List of Excipients in Branded Drug FROVATRIPTAN SUCCINATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	CELLULOSE, MICROCRYSTALLINE
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	HYPROMELLOSES
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	LACTOSE

Generic Drugs Containing FROVATRIPTAN SUCCINATE

Company	Ingredient	NDC	Excipient
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	ANHYDROUS LACTOSE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	CELLULOSE, MICROCRYSTALLINE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	HYPROMELLOSE

What are the Most Frequently-Used Excipients in FROVATRIPTAN SUCCINATE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
2	HYPROMELLOSE

Frovatriptan Succinate Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Frovatriptan succinate is an established, genericized oral migraine product with limited current patent protection and a low-complexity immediate-release tablet platform. The strongest commercial opportunities are differentiated oral delivery, improved swallowability, dose flexibility, and lifecycle products that address menstrual migraine and patients who cannot tolerate conventional tablets. Excipient selection should prioritize rapid dissolution, chemical stability, low tablet weight, taste control, and regulatory simplicity rather than novel composition-of-matter protection.

What is the FDA regulatory status of frovatriptan succinate?

Frovatriptan succinate is an FDA-approved prescription drug for the acute treatment of migraine attacks with or without aura in adults. The reference product, Frova, was approved as a 2.5 mg oral tablet under NDA 020786. Frovatriptan is a selective serotonin 5-HT1B/1D receptor agonist in the triptan class.[1]

Attribute	Frovatriptan succinate
Reference product	Frova
Active ingredient	Frovatriptan succinate
Strength	2.5 mg frovatriptan-equivalent tablet
Dosage form	Immediate-release oral tablet
FDA pathway	505(b)(1) reference NDA; ANDA generic pathway
Indication	Acute treatment of migraine with or without aura
Prescription status	Prescription-only
Controlled substance	No
Biosimilar pathway	Not applicable
Current market structure	Genericized small-molecule market

The approved product is an immediate-release tablet, not an extended-release, orally disintegrating, buccal, nasal, injectable, or transdermal product. That leaves room for lifecycle products, although any new dosage form would require a separate FDA regulatory strategy.

What excipients are used in frovatriptan tablets?

The reference Frova tablet uses a conventional immediate-release excipient system. Public labeling identifies lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, and magnesium stearate in the tablet core. The film coating contains standard coating materials, including hypromellose, titanium dioxide, polyethylene glycol, and colorants.[1,2]

The formulation architecture is commercially important because it is difficult to create meaningful differentiation through ordinary tablet excipients alone. A generic manufacturer can use a different excipient system if it demonstrates pharmaceutical equivalence, bioequivalence, stability, and acceptable manufacturing performance.

Core excipient functions

Excipient class	Typical function in frovatriptan tablet	Commercial rationale
Lactose monohydrate	Diluent and compressibility aid	Low cost and established regulatory history
Microcrystalline cellulose	Filler, binder, disintegration support	Improves tablet robustness at low dose
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup
Colloidal silicon dioxide	Glidant and flow aid	Helps control low-dose blend uniformity
Magnesium stearate	Lubricant	Supports ejection and manufacturing efficiency
Hypromellose	Film former	Protects tablet and improves appearance
Polyethylene glycol	Coating plasticizer	Reduces coating brittleness
Titanium dioxide or iron oxides	Opacifier or colorant	Product identification and visual differentiation

Frovatriptan is a low-dose active ingredient. Content uniformity, blend segregation, and lubricant sensitivity are therefore more important than bulk drug loading. The active ingredient is present in a small quantity relative to the tablet mass, making the choice of carrier, mixing order, particle-size distribution, and granulation process material to commercial quality.

How should manufacturers design a generic frovatriptan excipient system?

The most defensible strategy is a conventional immediate-release tablet with a robust, well-understood excipient platform. The formulation should target rapid disintegration without creating excessive friability, sticking, or dissolution variability.

Direct compression

Direct compression is attractive for a generic frovatriptan product because it reduces processing steps and avoids exposure to water or heat. A practical platform would use:

• Microcrystalline cellulose or a co-processed filler-binder
• Lactose or mannitol as a diluent
• Crospovidone or sodium starch glycolate as a superdisintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate at a tightly controlled concentration
• A standard aqueous or solvent-minimized film coating

The main risk is blend uniformity. Frovatriptan content is low, so direct compression requires control of particle-size differences and segregation during transfer and hopper discharge.

Wet granulation

Wet granulation may improve content uniformity and compactability if the active ingredient has poor flow or poor distribution in a direct-compression blend. It also can reduce segregation during downstream processing.

The disadvantages are higher manufacturing cost, longer processing time, and possible sensitivity to moisture. A wet-granulated formulation would require stability work focused on assay, degradation products, dissolution, and tablet hardness after storage.

Dry granulation

Roller compaction can provide a middle-ground option. It reduces water exposure while improving flow and bulk density. The main technical concern is over-compaction, which can slow disintegration and dissolution. This is particularly relevant when the commercial objective is a rapid-onset migraine product.

What excipient opportunities exist for frovatriptan lifecycle products?

The largest opportunities involve patient-facing delivery improvements rather than a conventional generic tablet.

Orally disintegrating tablet

An orally disintegrating tablet, or ODT, could address patients who experience nausea, have difficulty swallowing during migraine, or need administration without water. Suitable excipient technologies include:

• Mannitol for mouthfeel and cooling sensation
• Crospovidone or low-substituted hydroxypropyl cellulose for rapid disintegration
• Microcrystalline cellulose or silicified microcrystalline cellulose for structure
• Copovidone or povidone for binding
• Sucralose, aspartame, or acesulfame potassium for taste masking
• Flavors such as mint or citrus, subject to stability and patient acceptability
• Magnesium stearate or sodium stearyl fumarate for lubrication

An ODT creates a meaningful formulation development burden. Frovatriptan has a bitter active pharmaceutical ingredient profile typical of many low-dose amine-containing drugs. Taste masking is therefore a central issue. Simple sweetening may be insufficient, particularly if the tablet disintegrates rapidly in the oral cavity.

Potential taste-control methods include polymer coating of drug particles, ion-exchange resins, cyclodextrin complexes, and multiparticulate encapsulation. These approaches can create formulation patent opportunities, but they also increase manufacturing complexity and may affect dissolution.

Orally disintegrating mini-tablet

A mini-tablet or low-mass ODT could differentiate the product through easier administration and lower mouth residence time. It may also permit flexible dosing through multiple units, although the approved dose is 2.5 mg and any alternative dosing concept would need regulatory justification.

Buccal or sublingual delivery

A buccal or sublingual product could theoretically provide rapid delivery and bypass some gastrointestinal limitations. The commercial case is less certain because frovatriptan has a relatively long half-life compared with several other triptans. A faster onset may still have value, but the product would compete with established nasal and injectable migraine therapies.

A buccal product would require control of:

• Mucoadhesion
• Salivary dissolution
• Local irritation
• Dose uniformity
• Taste and mouthfeel
• Drug release under variable saliva conditions

Multiparticulate capsules

Taste-masked pellets or granules in a capsule could offer a platform for rapid release and flexible formulation. The format may be useful where tablet compression produces poor content uniformity or where a manufacturer wants a differentiated dosage form without developing a complex device.

The regulatory burden would exceed that of a conventional tablet because the applicant would need to demonstrate consistent multiparticulate manufacture, capsule fill uniformity, dissolution, and stability.

What formulation patents could protect frovatriptan products?

A new patent position would most likely arise from a specific formulation or manufacturing process rather than from frovatriptan itself. Potential claim categories include:

1. Orally disintegrating tablets with defined disintegration times.
2. Taste-masked frovatriptan particles using a polymer coating or ion-exchange resin.
3. Specific excipient ratios that improve content uniformity or dissolution.
4. Low-moisture formulations with improved chemical stability.
5. Multiparticulate dosage forms with defined particle-size distributions.
6. Buccal or sublingual films with controlled residence time.
7. Manufacturing processes that reduce segregation or degradation.
8. Combination products containing frovatriptan and an antiemetic, subject to clinical and regulatory support.

A patent based only on substituting one conventional filler for another would generally be vulnerable to obviousness arguments unless the formulation produces an unexpected, measurable result. Stronger patent cases would link the excipient system to a defined technical effect, such as a statistically significant improvement in dissolution under discriminatory conditions, taste masking, stability, or content uniformity.

When did frovatriptan lose exclusivity?

Frovatriptan's principal small-molecule patent protection was historical and has expired. The foundational U.S. patent associated with frovatriptan was U.S. Patent No. 5,616,603, which issued in 1997 and reached the end of its effective patent term in the mid-2010s after applicable term adjustments and regulatory exclusivity considerations.[3]

The product has been subject to generic competition for years. That market position means a new manufacturer generally does not need to overcome the original composition-of-matter patent, but it must still evaluate current Orange Book listings, pending applications, trademarks, and any formulation-specific patents before launch.

What is the Orange Book status of Frova?

Frova was listed in the FDA Orange Book as a 2.5 mg tablet reference product. Historical Orange Book patent listings associated with Frova did not create a current blocking barrier comparable to an active composition-of-matter patent. The commercial significance of the Orange Book today is primarily regulatory and competitive:

• It identifies the reference listed drug.
• It identifies approved generic equivalents.
• It records any listed patents and use codes.
• It provides the reference for ANDA certification analysis.
• It helps define whether a Paragraph IV certification could trigger litigation.

A new ANDA applicant must conduct a current Orange Book review because patent listings, pediatric extensions, and use-code records are time-sensitive. A formulation applicant using a 505(b)(2) pathway would need a separate assessment of listed patents and the extent to which the proposed product relies on the reference product's safety and efficacy findings.

Which companies challenge or compete with Frova?

The competitive landscape includes generic manufacturers and branded migraine products with different delivery systems. Generic frovatriptan has been marketed or approved by multiple manufacturers, including large and mid-sized ANDA sponsors such as Teva, Mylan/Viatris, Dr. Reddy's, Apotex, and other regional suppliers, depending on market and time period.[4]

Frovatriptan competes clinically with:

• Sumatriptan, including tablets, nasal spray, and injection
• Rizatriptan
• Zolmitriptan
• Naratriptan
• Almotriptan
• Eletriptan
• Ubrogepant and rimegepant
• Lasmiditan
• CGRP preventive therapies for patients with recurrent migraine

Frovatriptan's commercial differentiation is its relatively long elimination half-life, reported at approximately 26 hours, compared with shorter-acting triptans.[1] That characteristic supports use cases involving recurrence of migraine symptoms and menstrual migraine, but it does not by itself create exclusivity.

What generic entry risks exist for frovatriptan?

Generic entry risk is high because the product is an established immediate-release small molecule with no biosimilar complexity and a conventional oral dosage form.

Regulatory risks

The principal regulatory risks are:

• Failure to demonstrate bioequivalence.
• Dissolution differences caused by formulation changes.
• Content-uniformity failures at the 2.5 mg strength.
• Stability problems related to moisture or excipient compatibility.
• Inadequate control of nitrosamines or other process-related impurities, where applicable.
• Labeling or inactive-ingredient differences that affect tolerability.

Commercial risks

The main commercial risks are price erosion, limited market size, low physician switching, and pharmacy substitution pressure. A standard tablet is unlikely to command a durable premium unless it has a clear supply, packaging, adherence, or patient-experience advantage.

Patent and litigation risks

The foundational product patent is expired. A new entrant still must evaluate:

• Any later-listed formulation patent.
• Use patents covering a particular indication or patient population.
• Patent claims directed to an ODT, film, or taste-masked formulation.
• Trade dress and trademark restrictions.
• ANDA litigation arising from Paragraph IV certifications.

A conventional generic tablet is more likely to face commercial price competition than significant patent litigation. A differentiated 505(b)(2) product could create a new patent estate but would also attract more direct scrutiny from incumbent suppliers.

How strong is the current patent estate for frovatriptan?

The patent estate is weak for an ordinary immediate-release tablet and potentially stronger for a newly developed delivery system.

Asset type	Current commercial strength
Original frovatriptan molecule patent	Low; expired
Conventional immediate-release tablet	Low unless supported by a specific later patent
ODT with ordinary excipients	Moderate to low; vulnerable if obvious
Taste-masked ODT	Moderate if supported by unexpected performance data
Buccal or sublingual film	Potentially moderate to strong if technically differentiated
Manufacturing process	Variable; strongest where process control produces measurable quality benefits
Method-of-use patent	Limited unless tied to a novel, specific clinical use
Combination product	Potentially stronger, but requires clinical and regulatory investment

Patent strength will depend on claim breadth, prior art, enablement, obviousness, and whether the formulation produces a clinically or analytically meaningful benefit. The most defensible claims would combine composition limits with performance parameters and stability data.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are manageable for a standard tablet but rise quickly for specialty delivery systems.

Standard tablet barriers

A conventional product requires:

• Reliable low-dose blending.
• Control of segregation.
• Consistent tablet hardness and friability.
• Rapid and reproducible disintegration.
• Stable film coating.
• Commercial-scale dissolution matching.
• Validated analytical methods for assay and impurities.

ODT and taste-masked product barriers

Specialty products require additional controls for:

• Drug-particle coating uniformity.
• Taste-masking durability.
• Moisture uptake.
• Mechanical strength during packaging.
• Mouthfeel and residual grittiness.
• Rapid disintegration after long-term storage.
• Packaging in high-barrier blisters or desiccant-protected bottles.

These technical barriers can support a more defensible patent position, but they also reduce the number of qualified contract manufacturers and increase cost of goods.

What licensing deals could support a frovatriptan product?

Licensing opportunities are more likely to involve formulation technology than the active ingredient. Relevant targets include:

• ODT platforms.
• Taste-masking technologies.
• Buccal-film manufacturing.
• Multiparticulate coating systems.
• Low-dose blend-uniformity technologies.
• Specialty migraine combinations.
• Regional commercialization rights.

A license should be evaluated against the limited revenue pool of generic frovatriptan. A high upfront payment or royalty structure would be difficult to justify for an undifferentiated 2.5 mg tablet. Technology licensing becomes more rational where the product has a clear premium channel, differentiated reimbursement, hospital use, or a broader migraine portfolio strategy.

No major current licensing transaction is required to commercialize a standard generic frovatriptan tablet. The principal opportunity is an internal formulation program or a targeted platform license with low fixed cost.

What revenue exposure exists for frovatriptan?

Frovatriptan is a mature, relatively small migraine product. The reference brand's revenue exposure has declined with generic entry, and standalone frovatriptan sales are not generally disclosed by manufacturers in public financial reporting.

The most realistic revenue models are:

Product strategy	Price potential	Development risk	Commercial outlook
Standard generic tablet	Low	Low	Volume and supply-driven
Premium packaging or adherence format	Low to moderate	Low to moderate	Niche opportunity
ODT	Moderate	Moderate	Patient-experience differentiation
Taste-masked ODT	Moderate to high	Moderate to high	Stronger lifecycle case
Buccal film	High if clinically differentiated	High	Requires substantial development
Combination product	Variable	High	Depends on clinical evidence
Authorized generic	Low	Low	Useful for channel access

The strongest near-term opportunity is a low-cost generic with reliable supply and a differentiated ODT or taste-masked variant. The weakest strategy is investing heavily in a conventional tablet without a supply, price, geographic, or channel advantage.

How does frovatriptan compare with other triptans?

Frovatriptan has a longer half-life than most triptans, which may help reduce recurrence in some patients. Its disadvantages include a smaller commercial base, limited dosage-form diversity, and competition from newer CGRP-directed therapies.

Product	Main differentiation	Excipient opportunity
Frovatriptan	Long half-life; 2.5 mg tablet	ODT, taste masking, menstrual-migraine positioning
Sumatriptan	Broad dosage-form range	Difficult to differentiate on tablet alone
Rizatriptan	Established ODT competition	Stronger direct competition in orally disintegrating format
Zolmitriptan	Tablet and nasal options	Nasal and ODT lifecycle strategies
Naratriptan	Oral product and tolerability profile	Limited but possible adherence differentiation
Ubrogepant	CGRP antagonist; non-triptan mechanism	Higher-value branded formulation space
Rimegepant	ODT and preventive/acute use	Stronger branded delivery benchmark

Frovatriptan's ODT opportunity would face direct competition from existing orally disintegrating migraine products. The product would need superior taste, disintegration, packaging, price, or supply reliability.

What generic launch scenarios are most commercially credible?

Scenario 1: Conventional low-cost ANDA

This is the lowest-risk route. The sponsor uses a conventional immediate-release tablet, matches the reference product's dissolution profile, and competes through price and supply. Patent risk is limited because the core product patent is expired.

Scenario 2: Improved ODT under a 505(b)(2) strategy

This route targets migraine patients with nausea or swallowing difficulty. It requires stronger clinical and formulation justification and may support differentiated claims. The commercial opportunity is larger than a standard generic tablet, but development and market-access risk are also higher.

Scenario 3: Taste-masked ODT or buccal product

This approach offers the strongest potential differentiation. It also creates the highest technical risk, including taste persistence, dose release, stability, manufacturing yield, and clinical acceptance.

Scenario 4: Regional supply and licensing platform

A manufacturer could use an existing ODT or film platform and license rights in selected markets. This reduces internal development time but requires careful control of royalties, manufacturing transfer, regulatory ownership, and patent scope.

Key Takeaways

• Frovatriptan succinate is an established 2.5 mg immediate-release tablet with generic competition.
• The original composition-of-matter patent estate is expired; conventional generic entry is primarily a regulatory and commercial exercise.
• The reference formulation uses standard excipients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and conventional film-coating materials.
• Low-dose content uniformity and blend segregation are the central formulation risks.
• The best excipient-led opportunity is an ODT or taste-masked ODT aimed at migraine-associated nausea and difficulty swallowing.
• Conventional excipient substitution alone is unlikely to create strong patent protection.
• Taste masking, multiparticulate delivery, buccal films, and defined stability or dissolution advantages offer stronger patent possibilities.
• No biosimilar risk exists because frovatriptan is a small molecule.
• A standard generic tablet has low development risk but limited pricing power.
• A differentiated delivery system has greater revenue potential but requires more substantial regulatory, manufacturing, and intellectual-property investment.

FAQs

Can mannitol replace lactose in a frovatriptan tablet?

Yes. Mannitol can replace lactose as a diluent, particularly in an ODT, where its mouthfeel and cooling effect may improve patient acceptability. The change requires evaluation of hardness, friability, disintegration, dissolution, stability, and bioequivalence.

Is crospovidone preferable to sodium starch glycolate for frovatriptan ODTs?

Crospovidone may provide faster water wicking and lower gel formation, which can support rapid ODT disintegration. The preferred superdisintegrant depends on tablet porosity, compression force, particle size, and dissolution performance.

Does frovatriptan require a biosimilar application?

No. Frovatriptan is a chemically synthesized small molecule. Generic products are submitted through the ANDA pathway when they meet applicable pharmaceutical-equivalence and bioequivalence requirements.

Could a frovatriptan nasal product obtain new exclusivity?

A new nasal product could potentially receive regulatory exclusivity or patent protection if it qualifies as a new drug product and has supporting formulation or clinical differentiation. It would not automatically inherit the exclusivity status of the original tablet.

Is an ODT frovatriptan product commercially attractive?

An ODT is commercially plausible because migraine attacks can involve nausea and difficulty swallowing. Its success would depend on taste, disintegration speed, packaging stability, reimbursement, and whether the product can obtain a price premium over generic tablets.

References

1. U.S. Food and Drug Administration. (2011). Frova (frovatriptan succinate) tablets prescribing information. FDA.
2. National Library of Medicine. (n.d.). Frova- frovatriptan succinate tablet, film coated. DailyMed.
3. U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,616,603.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. FDA.